Compare safe note vs convertible note across structure, cost, and flexibility to choose the right instrument for your next fundraising round.
By Omer Aydin ·
SAFEs are simpler, cheaper to issue, and now dominate pre-seed rounds, making them the default for most early-stage US tech startups. Convertible notes suit founders who need debt-instrument flexibility, are raising outside the US, or are working with investors who require an interest rate and maturity date. Your stage, jurisdiction, and investor preferences should drive the choice.
Both instruments let you raise money today and delay a formal valuation conversation until a later priced round. But they differ fundamentally in legal structure: a convertible note is debt, and a SAFE is not. That distinction shapes everything from your balance sheet to your investor's enforcement rights. Before you send a term sheet, you need to understand the mechanics of each.
This article covers the structural differences between SAFEs and convertible notes. It is not legal, tax, or securities advice. Have your company's counsel review any instrument before you issue it.
SAFEs and convertible notes both convert into equity at a future priced round, but they sit in very different legal categories. The table below compares the features that matter most to founders choosing between them.
| Feature | SAFE Note | Convertible Note |
|---|---|---|
| Legal classification | Equity-like agreement (not debt) | Debt instrument |
| Accrues interest | No | Yes |
| Has maturity date | No | Yes |
| Valuation cap | Optional | Optional |
| Discount rate | Optional | Optional |
| Repayment obligation | No | Yes (if not converted) |
| Typical stage | Pre-seed to seed | Pre-seed to seed |
| US market share (pre-seed, Q1 2026) | ~93% | Remainder |
Scope note: market share figures reflect US pre-seed rounds on the Carta platform. Features listed reflect standard terms; actual terms vary by negotiation.
Market adoption tells a clear story. Carta data shows SAFEs reached 93% of pre-seed rounds in Q1 2026. An earlier snapshot from Q3 2024 put SAFE share at 88%, with convertible notes at 12%. The direction of travel is consistent: SAFEs have become the standard instrument for early US fundraising.
According to Osler's 2026 report, SAFEs represented 51.8% of all convertible securities issued in 2025, confirming that convertible notes still appear in a meaningful share of rounds, particularly at seed and beyond.
A SAFE (Simple Agreement for Future Equity) gives an investor the right to receive equity in a future priced round, with no interest, no maturity date, and no repayment obligation. It is not a loan. If the company never raises a priced round, the SAFE does not automatically become repayable debt.
The key economic terms in a SAFE are the valuation cap, the discount rate, or both. The valuation cap sets a ceiling on the price at which the investor's money converts into shares. The discount rate gives the investor shares at a lower price than new investors pay in the priced round.
A simple worked example: You issue a SAFE with a valuation cap. If your Series A prices the company at twice that cap, the SAFE investor converts at the cap price, receiving twice as many shares per dollar as the Series A investors. That is the economic reward for investing early.
Post-money SAFEs, which calculate dilution based on the cap table after the SAFE is issued, have become the dominant structure, accounting for 90.7% of all SAFEs issued in 2025. This structure gives both founders and investors a clearer picture of ownership percentages before a priced round closes.
On discount rates, the data is specific: according to Carta, 63% of SAFEs that include a discount term use a 20% rate. That figure gives you a useful anchor when negotiating, though the right rate for your round depends on your stage and investor expectations.
Because a SAFE carries no repayment obligation, it does not appear as a liability on your balance sheet. Investors in a SAFE also have fewer enforcement tools than debt holders, which is one reason some investors, particularly outside the US, prefer convertible notes. For a deeper look at how SAFEs affect your ownership structure over time, the cap table impact modeling guide for convertible notes walks through the dilution math in detail.
A convertible note is a short-term debt instrument. The investor loans money to the company, and that loan converts into equity at a future priced round, typically at a discount to the round price or subject to a valuation cap. If no conversion event occurs before the maturity date, the company may be required to repay the principal plus accrued interest.
That debt classification has real consequences. A convertible note sits on your balance sheet as a liability. The company owes the investor money in a way that a SAFE does not create. Maturity dates can create repayment pressure if a priced round takes longer than expected.
A worked example: You raise a sum on a convertible note with an annual interest rate, an 18-month maturity, and a discount rate. If you close a Series A before maturity, the principal plus accrued interest converts into shares at the agreed discount to the Series A price. If you do not close a priced round within 18 months, the note matures and the investor can request repayment or negotiate an extension.
The term "convertible loan" is sometimes used for instruments that function similarly to convertible notes, particularly in contexts outside the US. The underlying mechanics, accruing interest, a fixed maturity, and conversion into equity at a later round, are comparable, though the legal treatment can differ by jurisdiction.
Convertible notes typically involve more complex legal negotiation and higher drafting costs than SAFEs. That added complexity is one reason the instrument has lost ground to SAFEs at the pre-seed stage in the US, even as it remains common in later seed rounds and in markets where debt instruments are more familiar to local investors. According to Carta data cited by Stripe, SAFEs held 88% of pre-seed rounds in Q3 2024, leaving convertible notes with the remainder.
Neither instrument is objectively better. The right choice depends on your stage, your investors, and how much legal complexity you want to manage before your first priced round.
SAFE note advantages for founders:
SAFE note drawbacks:
Convertible note advantages for founders:
Convertible note drawbacks:
According to Osler's 2026 data, SAFEs made up 51.8% of all convertible securities issued in 2025, a figure that reflects how decisively the market has moved toward the simpler instrument at early stages.
SAFEs and convertible notes both defer the valuation question. A priced equity round answers it directly, which is sometimes the right call.
A priced round makes sense when a lead investor insists on a specific ownership percentage, when institutional investors require preferred stock protections, or when your cap table already holds several SAFEs at different caps and you want to resolve the accumulated dilution uncertainty in one step. The tradeoff is legal overhead: a term sheet, a stock purchase agreement, amended articles of incorporation, and often a 409A valuation all add time and cost. For most pre-seed companies, that overhead is hard to justify before you have the traction to defend a specific valuation number.
For a direct comparison of how SAFEs and FAST agreements affect cap table ownership, the FAST Agreement vs SAFE cap table comparison covers the mechanics in detail.
Start from your actual situation. The decision comes down to five factors: your stage, your geography, your investors' preferences, the complexity you can manage, and your timeline.
Beyond the mechanics, apply these filters. If you are raising a US pre-seed round and your investors are familiar with SAFEs, the SAFE is the simpler and faster path, and the market data above confirms that most early-stage investors have signed one before. If you are raising outside the US, or if your investors specifically request a debt instrument, a convertible note may be the only workable option. If a university technology transfer office or institutional co-investor has policies that restrict equity-like instruments, confirm their requirements before you choose a structure.
When in doubt, ask your lead investor which instrument they have signed before and which they prefer. Their answer will narrow the choice faster than any framework.
Before you issue a SAFE or a convertible note, your company needs to exist as a legal entity. Both instruments require a properly formed corporation, a US EIN, and a registered agent in your state of incorporation. Without those in place, you cannot sign binding agreements with investors or open a business bank account to receive funds.
Lovie Formation is a company formation service that handles entity setup, EIN application, and registered agent requirements for early-stage startups. Getting the entity right is the prerequisite step before any fundraising instrument can do its job. Once your entity is in place, staying current on ongoing obligations matters too; the LLC annual compliance guide covers the recurring requirements you need to track after formation.
Prices and plan limits verified as of October 2026.
If a company shuts down without ever closing a priced round, a SAFE does not automatically become repayable debt. Because a SAFE is not a debt instrument, there is no maturity date and no repayment obligation. In most cases, SAFE investors receive nothing if the company dissolves without a conversion event or acquisition. The specific outcome depends on the SAFE's terms and any liquidation provisions, so have counsel review the document before you issue it.
A convertible note creates repayment pressure on the company if a priced round is delayed past the maturity date. From an investor's standpoint, that maturity date can force a difficult choice: demand repayment from a cash-limited startup, or negotiate an extension. The note sits as a liability on the company's balance sheet, and the added legal complexity compared to a SAFE can slow the closing process. This is not investment advice; investors should consult their own counsel before committing to either instrument.
There is no structural rule that prevents a company from issuing SAFEs to some investors and convertible notes to others within the same financing round. In practice, mixing instruments adds complexity to the cap table and to future conversion calculations. Before doing so, have counsel confirm that the terms of each instrument are consistent and that the combination does not create unintended priority or dilution conflicts.
SAFEs were designed for the US market and are most familiar to US-based investors. Outside the US, particularly in markets where debt instruments are the investor norm, some investors may be unfamiliar with the SAFE structure or may prefer a convertible note for legal and regulatory reasons. If you are raising from international investors, confirm whether they have signed SAFEs before and whether local law treats the instrument as intended. Jurisdictional differences can affect enforceability, so local counsel is essential.
This is not tax advice, and you should have a qualified tax adviser review your specific situation before issuing either instrument. Generally, issuing a SAFE or a convertible note does not create an immediate taxable event for founders, because neither instrument transfers equity at the time of issuance. Conversion into equity at a later priced round may have tax implications depending on the instrument's terms, the company's structure, and the investor's jurisdiction. Do not rely on this summary as tax guidance.
SAFEs are the default instrument for US pre-seed fundraising because they are simpler, cheaper, and carry no repayment risk for the company. Convertible notes remain the right choice when investors require a debt structure, when you are raising outside the US, or when your investors are unfamiliar with SAFEs. Neither instrument is universally better; the right one matches your stage, your geography, and the expectations of the specific investors you are closing.
Confirm your entity is properly formed and in good standing before you issue either instrument. That is the prerequisite step, and everything else follows from there.
